MYLAN P157 (Metformin hydrochloride and pioglitazone hydrochloride 850 mg / 15 mg (base))
Pill imprint MYLAN P157 has been identified as Metformin hydrochloride and pioglitazone hydrochloride 850 mg / 15 mg (base).
Metformin/pioglitazone is used in the treatment of diabetes, type 2 and belongs to the drug class antidiabetic combinations. Risk cannot be ruled out during pregnancy. Metformin/pioglitazone 850 mg / 15 mg (base) is not subject to the Controlled Substances Act.
See also related documents.
- 850 mg / 15 mg (base)
- Elliptical / Oval
- Prescription only
More about metformin/pioglitazone
- Metformin extended-release/pioglitazone
- Pioglitazone/metformin extended-release tablets
- Metformin and pioglitazone
- More (2) »
- Pioglitazone and Metformin Tablets (FDA)
- Pioglitazone Hydrochloride/Metformin Hydrochloride (Wolters Kluwer)
Related treatment guides
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2015 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.